STOCK TITAN

Dss Inc Stock Price, News & Analysis

DSS NYSE

Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.

DSS, Inc. (NYSE American: DSS) generates news across a wide range of sectors, reflecting its role as a multinational company with diversified business lines in packaging, biohealth innovation, financial services, alternative trading, and real estate. The company’s press releases and regulatory disclosures highlight strategic transactions, capital markets developments, operational milestones, and portfolio optimization efforts.

News about DSS often covers corporate strategy and portfolio management, including spin-offs, asset sales, and transactions involving key subsidiaries. Examples include the sale of the Celios air purification asset to Impact BioMedical Inc., as well as a definitive merger agreement under which Impact BioMedical will be acquired through a reverse merger with Dr. Ashleys Limited, resulting in a new public company. These items illustrate DSS’s stated approach of unlocking value by advancing subsidiaries toward independent public listings and other exit opportunities.

Investors and followers of DSS can also expect updates on financial performance and corporate actions. The company reports on revenue trends, cash flow improvements, debt reduction, and asset monetization, such as the sale of a real estate facility and growth in rental income. Leadership communications, including letters to shareholders and announcements of executive appointments, provide additional context on strategic priorities, cost reduction initiatives, and the focus on core growth verticals.

Because DSS has subsidiaries in securities and investment management, its news flow includes developments at entities like Sentinel Brokers Company, Inc. and AmericaFirst Funds. These updates may involve regulatory approvals, such as FINRA authorization for underwriting activities, changes to mutual fund boards, and expansion of capital markets capabilities. For a comprehensive view of DSS-related developments, readers can use this news page to follow corporate strategy, subsidiary activity, and key financial and regulatory events over time.

Rhea-AI Summary

Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, received a patent from the USPTO for its 3FDB, a revolutionary mosquito repellent technology. This formulation enhances existing repellents like DEET by targeting multiple mosquito receptors to provide superior efficacy. The team discovered its active ingredients in the ghost orchid, which naturally repels mosquitoes. With the mosquito repellent market projected to reach $1.2 billion by 2025, DSS aims to leverage this innovation to save lives and address global health challenges related to mosquito-borne diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
-
Rhea-AI Summary

Document Security Systems, Inc. (DSS) has priced a public offering of 29 million shares at $1.50 per share, aiming for gross proceeds of approximately $43.5 million. The funds will support the company's expansion into new business lines and cover working capital needs. Additionally, underwriters have an option to purchase up to 15% more shares, potentially raising total proceeds to $50 million. The offering is filed under a shelf registration statement effective June 7, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.06%
Tags
-
Rhea-AI Summary

DSS acquires 24.9% of Sentinel Brokers Company, Inc. as part of its strategic expansion in the financial services sector. The agreement includes an option to buy an additional 50.1%, aimed at enhancing the ecosystem around DSS Securities. Established in 1996, Sentinel, a FINRA-registered broker-dealer, specializes in institutional trading of bonds and preferred stocks. DSS aims to leverage this acquisition to accelerate its digital securities business and capitalize on growth opportunities in the industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Document Security Systems (DSS) has launched a new subsidiary, DSS PureAir, focusing on air purification technology. Recent studies from the University of Florida show that products from Puradigm, a company DSS invested in, can effectively neutralize SARS-CoV-2 on surfaces, with a 97.7% decrease in viral infectivity after four hours. The air purifier market, valued at $10.7 billion in 2020, is projected to grow by 10% annually until 2028. DSS PureAir aims to capitalize on this growth with advanced purification solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary

Document Security Systems (DSS) announced that Proof Authentication Corporation has acquired 100% of DSS Digital, Inc., enhancing shareholder value by focusing on higher-return opportunities. The agreement allows DSS to license its anti-counterfeit technology to key customers while investing in growth areas like healthcare and renewable energy. The deal includes upfront cash and potential earn-out payments based on revenue targets. CEO Frank D. Heuszel highlighted the shift towards innovative solutions, indicating a strategic move to revitalize DSS's operations and drive market value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary

Document Security Systems (DSS) announced that its subsidiary, Premier Packaging Corporation, will relocate to a new 105,000 sq. ft. facility in Henrietta, NY, to accommodate rising customer demand. The move, expected by year-end 2021, is backed by up to $700,000 in state tax credits contingent on job creation. Premier aims to boost staffing by over 50% and enhance operational capacity through new investments. DSS's management emphasizes this transition as vital for Premier's growth and market leadership, aided by local government support.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
none
Rhea-AI Summary

DSS announced its subsidiary, DSS Biomedical, completed an equity investment in Vivacitas Oncology, a clinical-stage company specializing in difficult-to-treat cancers. This investment highlights DSS's commitment to addressing healthcare needs and provides Vivacitas with significant growth potential. Additionally, DSS Biomedical acquired Impact Oncology, whose principal assets include equity in Vivacitas. The agreements allow DSS to appoint two members to Vivacitas's board, further strengthening their partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary

DSS has launched Alset Solar, Inc., a subsidiary aimed at developing utility-scale solar farms. This initiative targets underutilized and contaminated lands to generate clean energy, thereby addressing community concerns about land use. Melissa Sims, Director of Alset Solar, emphasizes the potential of solar energy to combat climate change and enhance energy access. Alset Solar will focus on key markets in the US sunbelt, working closely with communities to repurpose blighted lands. This move aligns with the increasing demand for renewable energy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary

Document Security Systems (DSS) announced that its subsidiary Impact BioMedical received a notice of allowance from the USPTO for a patent regarding its Equivir compound, which targets Ebola and Rhinovirus. This complements a prior patent for influenza treatment. Equivir employs FDA GRAS polyphenols to inhibit viral infections and is considered a strategic defense against emerging epidemics. The company aims to further develop and partner opportunities for Equivir as it capitalizes on its expanding intellectual property portfolio, enhancing long-term value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
Rhea-AI Summary

Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, received a notice of allowance from the USPTO for a patent on the Equivir compound, designed to mitigate the effects of Ebola and Rhinovirus. Equivir combines FDA GRAS eligible polyphenols, targeting viral infections through several mechanisms. CEO Frank D. Heuszel emphasized its extensive antiviral potential and possible partnerships. The compound has shown effectiveness against viral infections, including in-vitro studies for SARS COV2. This patent adds to DSS's intellectual property estate, enhancing its market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none

FAQ

What is the current stock price of Dss (DSS)?

The current stock price of Dss (DSS) is $0.9 as of April 6, 2026.

What is the market cap of Dss (DSS)?

The market cap of Dss (DSS) is approximately 9.3M.

DSS Rankings

DSS Stock Data

9.34M
3.98M
Packaging & Containers
Paperboard Containers & Boxes
Link
United States
WEST HENRIETTA

DSS RSS Feed